Gynecologic Cancer
Feature
Is pain or dependency driving elevated opioid use among long-term cancer survivors?
Rates of opioid prescribing were about 1.2 times higher overall among cancer survivors up to 10 years after diagnosis, compared with matched...
Expert Commentary
Does HPV testing lead to improved diagnosis of cervical dysplasia for patients with ASC-US cytology?
Yes, according to an analysis from the New Mexico HPV Pap Registry that looked at long-term outcomes of atypical squamous cells of undetermined...
Gynecologic Oncology Consult
Low malignant potential tumors of the ovary: A review
Surgeons who manage these tumors can safely consider fertility sparing procedures but should be prepared to completely resect all disease.
Gynecologic Oncology Consult
Optimizing HPV vaccination
Moving to a two-dose vaccine schedule in the under-15 age group will help improve vaccination completion rates but more needs to be done.
News from the FDA/CDC
Use of Pap smears, mammography on the decline
Trends by age group are similar between the two tests, but racial patterns differ.
Gynecologic Oncology Consult
Understanding the human papillomavirus
In her column, Dr. Emma Rossi reviews the fundamentals of HPV biology, epidemiology, and carcinogenesis.
Expert Commentary
Is sentinel lymph node mapping associated with acceptable performance characteristics for the detection of nodal metastases in women with endometrial cancer?
Yes. Sentinel lymph node (SLN) biopsy will accurately identify nodal metastases in 97% of women with nodal disease. Negative SLNs are accurate in...
Product Review
Product Update: Intrarosa, ZEJULA, Signia Stapling System, TYMLOS, Videssa Breast
NONESTROGEN PRODUCT FOR DYSPAREUNIAIntrarosa (prasterone 6.5 mg), from AMAG Pharmaceuticals and Endoceutics, Inc, is announced as the only FDA-...
Conference Coverage
PORTEC-3: Possible benefit with combined CT/RT in high-risk endometrial cancer
Women with stage III endometrial cancer in the combined CT/RT arm experienced a statistically significant 11% improvement in FFS – defined as...
Conference Coverage
DESKTOP III: Secondary surgery for recurrent OC improves PFS, TFST
CHICAGO – Secondary cytoreductive surgery resulted in a clinically meaningful increase in progression-free survival and time to first subsequent...
Gynecologic Oncology Consult
PARP inhibitors: New developments in ovarian cancer treatment
Maturing data from ongoing trials will likely expand the opportunity to use PARP inhibitors for the treatment of ovarian cancer.